Table 4 Relationships between clinicopathologic characteristics in patients with T1, T1a, and T1b melanomas and recurrence-free survival (RFS) by univariate and multivariable analysis.
From: Prognostic significance of acral lentiginous histologic type in T1 melanoma
RFS (univariate analysis) | ||||||
---|---|---|---|---|---|---|
T1 | T1a | T1b | ||||
Characteristic | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value |
Histologic type | ||||||
ALM vs. non-ALM | 3.70 (2.26, 6.05) | <0.001 | 3.81 (1.96, 7.42) | <0.001 | 3.54 (1.70, 7.35) | <0.001 |
Gender | ||||||
Female vs. Male | 0.62 (0.40, 0.97) | 0.035 | 0.61 (0.34, 1.12) | 0.11 | 0.66 (0.34, 1.27) | 0.21 |
Age | ||||||
Continuous | 1.06 (1.05, 1.08) | <0.001 | 1.08 (1.05, 1.10) | <0.001 | 1.04 (1.02, 1.07) | <0.001 |
Race/ethnicity | ||||||
Hispanic vs. Caucasian | 2.18 (0.79, 5.96) | 0.13 | 3.35 (1.03, 10.87) | 0.045 | 1.49 (0.28, 7.96) | 0.64 |
Other vs. Caucasian | 1.04 (0.15, 7.52) | 0.97 | 1.80 (0.25, 13.08) | 0.56 | 1.44 (0.08, 25.59) | 0.81 |
Clark level | ||||||
IV–V vs. I–III | 0.85 (0.48, 1.52) | 0.59 | 0.74 (0.26, 2.06) | 0.56 | 0.71 (0.34, 1.47) | 0.36 |
Breslow thickness | ||||||
Continuous | 4.31 (1.43, 12.94) | 0.009 | 5.92 (0.61, 57.91) | 0.13 | 1.44 (0.06, 34.84) | 0.82 |
Mitosis | ||||||
≥1/mm2 vs. <1/mm2 | 1.21 (0.77, 1.90) | 0.41 | 0.64 (0.29, 1.39) | 0.26 | 1.57 (0.79, 3.12) | 0.20 |
Ulceration | ||||||
Present vs. Absent | 1.90 (0.77, 4.69) | 0.17 | 1.45 (0.56, 3.71) | 0.44 | ||
Regression | ||||||
Present vs. Absent | 1.15 (0.72, 1.83) | 0.56 | 1.08 (0.58, 2.01) | 0.81 | 1.50 (0.74, 3.02) | 0.26 |
Tumor-infiltrating lymphocytes | ||||||
Brisk vs. Non-brisk/minimal | 0.51 (0.22, 1.17) | 0.11 | 0.50 (0.15, 1.62) | 0.25 | 0.48 (0.15, 1.56) | 0.22 |
Vertical growth phase | ||||||
Present vs. Absent | 1.18 (0.67, 2.08) | 0.56 | 1.00 (0.51, 1.96) | 1.00 | 0.99 (0.30, 3.25) | 0.99 |
Predominant cytology | ||||||
Spindle vs. Epithelioid | 0.84 (0.20, 3.45) | 0.81 | 0.89 (0.12, 6.49) | 0.91 | 0.74 (0.10, 5.60) | 0.77 |
Nevoid vs. Epithelioid | 2.50 (1.07, 5.85) | 0.035 | 1.67 (0.40, 6.97) | 0.49 | 2.98 (1.00, 8.89) | 0.050 |
Sentinel lymph nodes | ||||||
Positive vs. Negative | 5.92 (3.29, 10.65) | <0.001 | 5.70 (2.01, 16.18) | 0.001 | 5.03 (2.41, 10.49) | <0.001 |
Number of positive SLNs | ||||||
Continuous | 3.20 (1.44, 7.12) | 0.004 | 4.63 (0.41, 51.89) | 0.21 | 3.33 (1.23, 9.02) | 0.018 |
Systemic therapy | ||||||
Yes vs. No | 4.67 (2.25, 9.68) | <0.001 | 7.28 (2.60, 20.38) | <0.001 | 2.85 (1.01, 8.06) | 0.048 |
RFS (multivariate analysis) | ||||||
Histologic type | ||||||
ALM vs. non-ALM | 3.07 (1.05, 8.99) | 0.040 | ||||
Age | ||||||
Continuous | 1.07 (1.04, 1.09) | <0.001 | 1.10 (1.06, 1.14) | <0.001 | ||
Sentinel lymph nodes | ||||||
Positive vs. Negative | 6.23 (2.85, 13.62) | <0.001 | 18.38 (3.57, 94.68) | <0.001 | 7.05 (2.57, 19.32) | <0.001 |